MDM2 and P53 polymorphisms contribute together to the risk and survival of prostate cancer
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1465 views | HTML 2063 views | ?
Li Xue1,*, Xiujuan Han2,*, Rongrong Liu3, Ziming Wang1, Hecheng Li1, Qi Chen1, Peng Zhang1, Zhenlong Wang1 and Tie Chong1
1 Department of Urology, The Second Affiliated Hospital, Xi’an Jiaotong University, Xian, China
2 The Helmholtz Sino-German Research Laboratory for Cancer, Department of Pathology, Tangdu Hospital, The Fourth Military Medical University, Xian, China
3 Department of Pathology, School of Basic Medicine, Fourth Military Medical University, Xian, Shaanxi, China
* These authors have contributed equally to this work
Tie Chong, email:
Keywords: MDM2 gene; p53 gene; prostate cancer; risk; survival
Received: March 11, 2015 Accepted: April 08, 2015 Published: May 18, 2015
The p53 gene and MDM2 gene play critical roles in cell cycle arrest and apoptosis together. Here, we evaluated the associations of prostate cancer risk and survival with the joint effects of mdm2 and p53 polymorphisms. Totally 1,193 cases and 1,310 age frequency-matched controls were included in the study. Prostate cancer patients were followed to determine the intervals of overall survival and disease-free survival. The Pro72Arg Pro allele (homozygous and heterozygous) were significantly associated with prostate cancer risk with an odds ratio (OR) of 0.77 [95% confidence interval(CI), 0.64-0.93]. SNP309 T alleles were associated with a significantly decreased prostate cancer risk among Pro72Arg Pro alleles carriers (OR=0.79, 95% CI, 0.64-0.98). In addition, comparedwith the Pro72Arg Pro alleles and SNP309 G homozygous, patients carrying both SNP309 T alleles and Pro72Arg Arg homozygous had more favorable disease-free survival (hazard ratio [HR] = 0.59, 95% CI, 0.38-0.93). Our results indicated that SNP309 and Pro72Arg polymorphisms may jointly contributeto the etiology and prognosis of prostate cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.